Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant collagen scar gel
- Development stage
- Unknown
- Lead developer
- Suzhou Hao Microbial Medical Technology
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Topical
01
Overview
Recombinant collagen scar gel is a topical medical device developed by Suzhou Hao Microbial Medical Technology for the management and prevention of scars. The gel formulation contains recombinant collagen, which mimics human collagen to support tissue repair, promote wound healing, and regulate extracellular matrix deposition. By forming a protective, hydrating barrier over the affected skin, the gel helps to soften, flatten, and fade pathological scars, such as hypertrophic scars and keloids resulting from surgical procedures, trauma, or burns.
- Other names
- 重组胶原蛋白疤痕凝胶
02
Targets
HYAL (Hyaluronidase family (HYAL))NeuraminidaseMMP12 (Macrophage Metalloelastase)
Beyond the preview
Go deeper on recombinant collagen scar gel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant collagen scar gel.